Status:
UNKNOWN
A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Donafenib
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This trial is a single center observational real-world study. It is planned to include 300 patients with unresectable hepatocellular carcinoma (uHCC) treated with Donafenib. The purpose of the study w...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old;
- Histologically confirmed HCC or meet the clinical diagnostic criteria of HCC;
- Unresectable HCC;
- The doctor decided to use donafenib before the patient was enrolled in the study；
- Informed consent and willing to complete the study according to the protocol.
Exclusion
- Those who are participating in clinical trials of other antitumor drugs;
- Allergic to any component of Donafenib tablets;
- Patients with active bleeding, active peptic ulcer, drug uncontrollable hypertension or severe liver dysfunction;
- Pregnant or lactating women.
Key Trial Info
Start Date :
January 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05200221
Start Date
January 19 2022
End Date
March 30 2024
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital, Fudan University,
Shanghai, Shanghai Municipality, China, 200032